Patients with known human immunodeficiency virus (HIV) or hepatitis B or C are excluded
Patients known to be human immunodeficiency virus (HIV) positive may be enrolled if baseline cluster of differentiation (CD)4 count is > 500 cells/mm^3 AND not taking anti-retroviral therapy; patients with known hepatitis are not eligible unless there is a known negative hepatitis panel; (exception: previous history of hepatitis A infection that is not currently active is allowed); patients must not have any known uncontrolled underlying pulmonary disease
Patients must not have a known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection that is untreated and/or with a detectable viral load
Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration
Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration; patients who have completed curative therapy for HCV are eligible; patients with known human immunodeficiency virus (HIV) infection are eligible if they meet each of the following 3 criteria:\r\n* CD4 counts >= 350 mm^3\r\n* Serum HIV viral load of < 25,000 IU/ml and\r\n* Treated on a stable antiretroviral regimen
Participant is known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C
Known human immunodeficiency virus (HIV) infection and/or active hepatitis B infection (defined as presence of Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA).
Negative screening test results for human immunodeficiency virus (HIV), hepatitis B and C; if positive results are not indicative of true active or chronic infection, the subjects can enter the study after discussion with the principal investigator
Patients with known active infections with human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B (HBV), and hepatitis C virus (HCV) infections will not be considered for this trial; HIV+ patients on combination antiretroviral therapy are ineligible; testing for HIV or hepatitis is not required
Prior or current history of hepatitis B, hepatitis C or human immunodeficiency virus
Evidence of severe or uncontrolled systemic diseases including active liver disease (other than malignancy), active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Exclusion crtieria Part C
Patients with known human immunodeficiency virus (HIV) infection, infectious hepatitis, type A, B or C, active hepatitis, or hepatic insufficiency
Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis
12. Known to be human immunodeficiency virus (HIV) positive, hepatitis B, or hepatitis C positive;
Patients with known active hepatitis (i.e., hepatitis B or C) or human immunodeficiency virus (HIV) with detectable viral load (history of HIV with undetectable viral load is allowed)
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known active or chronic hepatitis B or C infection
Previously known infection with human immunodeficiency virus (HIV); or hepatitis B or hepatitis C infection.
Hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus; screening for chronic conditions is not required
Active hepatitis B virus (HBV) infection
History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known or suspected chronic active Epstein-Barr virus (EBV) infection, acute or chronic hepatitis C virus (HCV) infection
Subject has an active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or human T-lymphotropic virus (HTLV) as defined below:
Known human immunodeficiency virus or active hepatitis C viral infection
Patients with active Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Human immune deficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.
Known history of human immunodeficiency virus infection (HIV) or hepatitis C or active hepatitis B infection, unless the patient was diagnosed >10 years prior to enrollment and no evidence of active liver disease.
Active and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness; baseline viral assessment is not required in patients with no known infection
EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus
EXCLUSION CRITERIA FOR THIRD-LINE THERAPY: Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus
Current known active infection with HIV, hepatitis B virus, or hepatitis C virus
Positive serology for human immunodeficiency virus (HIV) or hepatitis C virus (HCV); presence in the serum of the antigen hemoglobin (HBs)
Has a known history of or screens positive for Human Immunodeficiency Virus (HIV), active chronic or acute Hepatitis B or Hepatitis C.
Subject with known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection or is known to be a carrier of hepatitis B or C.
Patients seropositive or PCR positive for the human immunodeficiency virus (HIV). Patients with evidence of Hepatitis B or Hepatitis C PCR positivity
Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligible
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C or active hepatitis
Known human immunodeficiency virus (HIV) or known active hepatitis B virus or hepatitis C virus infection
Positive for human immunodeficiency virus (HIV) or hepatitis B or C
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; similarly, patients with chronic or acute hepatitis C virus (HCV) or hepatitis B virus (HBV) infection are also ineligible; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowed
Positive human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection.
Known to be seropositive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)
Active infection, known human immunodeficiency virus infection, or positive test for hepatitis B surface antigen or hepatitis C.
Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection (hepatitis B carriers with normal liver function tests [LFTs] and undetectable viral loads are allowed)
Patients known to be seropositive for human immunodeficiency virus (HIV) and active hepatitis, even if liver function studies are in the eligible range
Is test positive for hepatitis C virus (HCV), hepatitis B virus (HBV) or human immunodeficiency virus (HIV) antibody.
Human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or concurrent illness, unrelated to the tumor, requiring active therapy
Known seropositive for human immunodeficiency (HIV) virus, hepatitis B surface antigen (HbsAg), or antibody to hepatitis C virus (anti-HCV)
No known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus-I and -II positive status.
Known human immunodeficiency virus (HIV) seropositivity or active hepatitis B or C viral infection
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted)
Immunocompromised patients (other than that related to the use of corticosteroids) including patients with a known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
Prior or current history of hepatitis B, hepatitis C or human immunodeficiency virus
Positive for HIV, hepatitis B, hepatitis C, syphilis or human T Cell leukemia virus (HTLV).
No known human immunodeficiency virus (HIV) positive, or active hepatitis infection
Known active hepatitis B infection, active hepatitis C infection or known human immunodeficiency virus (HIV) carrier
Patients with known active human immunodeficiency virus (HIV), hepatitis (hep) B, or hep C infection
Active hepatitis or human immunodeficiency virus infection
Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis A, B, or C (screening is not required).
History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Negative virology/serology for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) DNA
Subjects with known active human immunodeficiency virus, hepatitis B virus, or hepatitis C virus infection
Patients with human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection will be excluded
PHASE II EXCLUSION CRITERIA: Patients with human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection will be excluded
Current known active infection with HIV, hepatitis B virus, or hepatitis C virus.
Subject is seropositive for or has active viral infection with hepatitis B virus (HBV):
Subject is known to be seropositive for, or have an active infection with, hepatitis C virus (HCV).
Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection, and/or detectable virus.
Active hepatitis B virus (HBV) infection (chronic or acute)
Active hepatitis C virus (HCV) infection
Participant has a known history of human immunodeficiency virus (HIV) infection or hepatitis C virus (HCV), or requires treatment with protease inhibitors (testing not mandatory).
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known history of human immunodeficiency virus (HIV), active infection with hepatitis B virus (HBV), and/or hepatitis C virus (HCV)
Known history of human immunodeficiency virus (HIV), active infection with hepatitis B virus (HBV), and/or hepatitis C virus (HCV)
Active human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C infection.
Known chronic infections with human immunodeficiency virus (HIV), hepatitis B or C; participants with a history of resolved hepatitis A may be included in the trial
Any known human immunodeficiency virus (HIV) infection, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
No known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) seropositivity; testing is not required in absence of clinical suspicion
Have a serious concomitant systemic disorder that would compromise the participant's ability to adhere to the protocol, including active or chronic infection with human immunodeficiency virus (HIV), active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorders, or prior documented severe autoimmune or inflammatory disorders requiring immunosuppressive treatment.
Known chronic infection with human immunodeficiency virus (HIV) or viral hepatitis
Human immunodeficiency virus (HIV) or hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C.
Known positive test for hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)
Has known human immunodeficiency virus (HIV) and/or Hepatitis B or C infection(s).
Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus (HIV) infection.
Positive test for human immunodeficiency virus and/or active hepatitis B or hepatitis C or tuberculosis
Positive human immunodeficiency virus (HIV) test, active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection or active tuberculosis
History of human immunodeficiency virus (HIV), interstitial lung disease, active Hepatitis B or Hepatitis C, or ?Grade 3 immune-related AE with prior immunotherapy
Known infection with Human Immunodeficiency Virus (HIV), and/or active infection with hepatitis B, or hepatitis C.
Known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection or known history of tuberculosis
Active uncontrolled infection, including known history of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) or hepatitis B or C
Known active hepatitis A, B, or C virus infection
Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Serious concurrent illness or clinically-relevant active infection, including, but not limited to the following:\r\n* Known active hepatitis B or C\r\n* Known human immunodeficiency virus (HIV) infection\r\n* Varicella-zoster virus (shingles)\r\n* Cytomegalovirus infection\r\n* Any other known concurrent infectious disease, requiring IV antibiotics with 2 weeks of study enrollment
EXCLUSION - PROCUREMENT: Active infection with human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) (can be pending at this time)
Known immunodeficiency or known to have evidence of acute or chronic or human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C or other uncontrolled inter-current illnesses.
Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
Patients infected with hepatitis B, C or human immunodeficiency virus (HIV), unless they are on stable and effective antiviral treatment
Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligible
Known infection with human immunodeficiency virus or chronic infection with hepatitis B virus (hepatitis B surface antigen positive) or hepatitis C virus (anti hepatitis C virus positive)
Have a known human immunodeficiency virus (HIV) infection or known activated/reactivated hepatitis A, B, or C.
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or hepatitis B virus (HBV).
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or active hepatitis B virus (HBV) and hepatitis C virus (HCV)
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Active human immunodeficiency virus (HIV) or hepatitis B or C infection
Positive for HIV, hepatitis B, hepatitis C, syphilis or human T cell leukemia virus (HTLV).
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV or HCV infection, which will be allowed)
Have negative test result for human immunodeficiency virus (HIV) and hepatitis B or C testing
Participants with known history of human immunodeficiency virus (HIV) or active Hepatitis B or C virus
Subjects with a known history of human immunodeficiency virus 1 and 2, human T lymphotropic virus 1, hepatitis B virus, or active hepatitis C virus.
The patient has known positive status for human immunodeficiency virus active or chronic Hepatitis B or Hepatitis C.
Positive human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection.
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive; patients who have previously tested positive for hepatitis B core antibody may be eligible if they are confirmed to NOT have active disease and are on appropriate anti-viral therapy; no additional hepatitis or HIV testing is required for patients who have been evaluated during their induction and/or pre-transplant work-up and have had no clinical evidence of HIV, hepatitis B or hepatitis C since their last evaluation
Positive for human immunodeficiency virus (HIV) or hepatitis B or C
Known human immunodeficiency virus (HIV) or known hepatitis C virus (HCV) infection or active hepatitis B.
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known history of human immunodeficiency virus infection or current chronic/active hepatitis B or C infection.
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Hepatitis B and C negative (unless the result is consistent with prior vaccination or prior infection with full recovery); human immunodeficiency virus (HIV) negative
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Active infection with hepatitis C virus (HCV)
Human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) infection:\r\n* Seropositive for HIV antibody\r\n* Seropositive for hepatitis C or positive for hepatitis B surface antigen (HbsAG)
Ongoing or active infection, known human immunodeficiency virus positive, active hepatitis B or C infection.
Known seropositive and requiring anti-viral therapy for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) defined by polymerase chain reaction (PCR)
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive; hepatitis and HIV testing are not required prior to the start of treatment
Active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
Donors who are HIV-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; testing is not required unless clinically suspected
Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
Known infection of, or who test positive for, human immunodeficiency virus, hepatitis B virus or hepatitis C virus.
Known Human Immunodeficiency Virus (HIV) infection and/or active Hepatitis B or Hepatitis C infection
Human immunodeficiency virus (HIV) positivity or evidence of active hepatitis C virus.
Patients must not have known human immunodeficiency virus (HIV) infection or active hepatitis B or C infections
Patients with known human immunodeficiency virus (HIV) infection or hepatitis B or C infection; HIV testing is not mandated and is to be performed at the discretion of the treating investigator
Known immunodeficiency, human immunodeficiency virus (HIV) positivity, hepatitis B, or hepatitis C
Known active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of prior hepatitis B virus vaccination are eligible
Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
Positive serology for human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Known infection with human immunodeficiency virus (HIV); hepatitis B is allowed only if viral load is undetectable and if on anti-hepatitis B therapy like entecavir; hepatitis C is allowed only if viral load is undetectable, and if the patient has received curative therapy
Known active human immunodeficiency virus (HIV) or hepatitis B or C infection
Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to trial registration. Patients who have completed curative therapy for HCV are eligible. Patients with known human immunodeficiency virus (HIV) infection are eligible if they meet each of the following 3 criteria:\r\n* CD4 counts >= 350 mm^3\r\n* Serum HIV viral load of < 25,000 IU/ml and\r\n* Treated on a stable antiretroviral regimen.
Active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV); patients with HBV and/or HCV sero-positivity only will be eligible, if nucleic acid amplification testing (NAT) is negative
Known hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) infection or active hepatitis B (defined as hepatitis B surface antigen–positive) or C (defined as hepatitis C antibody–positive)
Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
Known human immunodeficiency virus or active hepatitis B or C viral infection
No human immunodeficiency virus (HIV) infection or active hepatitis B or C.
Known active hepatitis B (HBV) or hepatitis C (HCV) infection or known human immunodeficiency virus (HIV) infection.
Known seropositive for or active viral infection with, human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
Human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) positive patients on antiviral drugs are excluded due to the absence of previous experience with concurrent use of antiviral medications and the investigational drug product to be evaluated in the current study and possible for adverse pharmacokinetic and/or pharmacodynamic interactions
Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).
Human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; HIV positive patients will be excluded due to a theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection
Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator’s opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or known active infection including chronic active hepatitis B, hepatitis C and human immunodeficiency virus (HIV); screening for chronic conditions is not required; patients with chronic hepatitis B virus (HBV) with negative HBV viral load on appropriate antiviral therapy will be permitted, if able to continue appropriate antiviral therapy throughout treatment period
Human immunodeficiency virus (HIV) positive; active hepatitis B or C;
Negative antiviral serology for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.
Active and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness (human immunodeficiency virus [HIV] testing is not required), including patients who have an active infection requiring systemic therapy
Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
As judged by the Investigator, has any evidence of severe or uncontrolled diseases such as active bleeding diatheses, or has an active viral infection of human immunodeficiency virus (HIV), human papilloma virus (HPV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV)
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration
Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
Has active human immunodeficiency virus infection that is uncontrolled (increasing plasma HIV RNA viral load) with medication, or has an active hepatitis B or C infection
Documented human immunodeficiency virus (HIV) infection or positive serology, active bacterial infections, serologic or polymerase chain reaction (PCR) evidence for active or chronic hepatitis B or hepatitis C
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Known infection caused by human immunodeficiency virus (HIV) or active hepatitis B or C
Positive serology for hepatitis B or C, or known human immunodeficiency virus infection (HIV)
Active uncontrolled infection at study enrollment including known diagnosis of human immunodeficiency virus or chronic active hepatitis B or C infection
Patients with known active human immunodeficiency virus (HIV), hepatitis (Hep) B, or Hep C infection will be excluded; if not clinically indicated, the patients do not need to be tested
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C.
Known history of human immunodeficiency virus (HIV) seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment; patients receiving prophylactic antibiotics (e.g., for prevention of urinary tract infection or chronic obstructive pulmonary disease) are eligible
Has serious concomitant illnesses, such as: cardiovascular disease (uncontrolled congestive heart failure, hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmia), bleeding disorders, autoimmune diseases, severe obstructive or restrictive pulmonary diseases, active systemic infections, and inflammatory bowel disorders; this includes human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or active hepatitis B virus (HBV) and hepatitis C virus (HCV)
Active HIV, hepatitis C virus, or hepatitis B virus infection(s)
Patients with known positivity for human immunodeficiency virus (HIV), or hepatitis C; baseline testing for HIV and hepatitis C is not required
Donors who are human immunodeficiency virus (HIV)-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection
History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
Known to be positive for human immunodeficiency virus (HIV) or infectious hepatitis (type B or C)
Patients with other viral infections are ineligible:\r\n* Known to have acute or chronic active hepatitis B or hepatitis C infection\r\n* Known to have human immunodeficiency virus (HIV) infection\r\n* Prior therapy with viral-based tumor vaccine\r\n* Received live vaccine within 28 days prior to enrollment
Has active co-infection with HBV and hepatitis D virus (HDV)
Subject has known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection or is known to be a carrier of hepatitis B or C.
Subjects with known human immunodeficiency virus (HIV), acute chronic hepatitis B virus surface antigen (HBsAg) or hepatitis C virus. (HIV-positive subjects are ineligible because of the potential for pharmacokinetic interactions of antiviral therapy with IACS-010759.)
Active and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness (HIV testing is not required)
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Is human immunodeficiency virus (HIV) positive or has evidence of active hepatitis C virus or active hepatitis B virus; if initial test shows a positive result, no further testing will be done
Known positive test for human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), hepatitis A, hepatitis B, hepatitis C, or cytomegalovirus (CMV)
Patients with clinically evident human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or Epstein-Barr virus (EBV) infection are excluded
Known or active human immunodeficiency virus (HIV) infection or active hepatitis B or C viral infection
Active infection requiring systemic therapy including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) is NOT permitted
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted)
Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
Known history of human immunodeficiency virus (HIV) positivity or active hepatitis C or B - chronic asymptomatic viral hepatitis is allowed
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus (testing not required prior to enrollment)\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters
Patients known to have acute or chronic active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV).
Known human immunodeficiency virus (HIV) positive serology or chronically active hepatitis B or C.
Current active infections with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), hepatitis B, and hepatitis C requiring treatment
Known evidence of an active infection requiring systemic therapy such as human immunodeficiency virus (HIV), active hepatitis, or fungal infection.
Known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)
Patients with a known chronic immunocompromised state, human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection
Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses, or renal transplant, including any patient known to have hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) will be excluded; patients with HIV who have adequate CD4 count, not requiring antiretroviral medication, may be enrolled
Human immunodeficiency virus (HIV), active hepatitis B or C
Any evidence of a severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease, active infection (including hepatitis B, hepatitis C, human immunodeficiency virus [HIV]), active bleeding diatheses or renal transplant
Known active hepatitis A, B or C virus infection
Acute hepatitis or known human immunodeficiency virus (HIV)
Participants with progressive neurological dysfunction that would confound the evaluation of neurological and other toxicities; any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any participant with known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Patients infected with hepatitis B, C or human immunodeficiency virus (HIV), unless they are on stable and effective antiviral treatment
Patients with active hepatic disease, liver cirrhosis, or known hepatitis B virus (HBV)/hepatitis C virus (HCV) infection
Human immunodeficiency virus (HIV) seropositivity, or active hepatitis B or C infection based on testing performed within 4 weeks of enrollment.
Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (hepatitis B surface antigen [HBsAg] positive) or hepatitis C virus (anti-HCV positive).
Patients with conditions requiring immunosuppressive medications or chronic infections (including human immunodeficiency virus [HIV] infection, hepatitis B and C)
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Serious concurrent illness or clinically-relevant active infection, including, but not limited to the following:\r\n* Known active hepatitis B or C\r\n* Known human immunodeficiency virus (HIV) infection\r\n* Varicella-zoster virus (shingles)\r\n* Cytomegalovirus infection\r\n* Any other known concurrent infectious disease, requiring IV antibiotics within 2 weeks of study enrollment
CRITERIA FOR SCREENING: Known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Known history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) -related illness
Have any condition or illness that, in the opinion of the investigator would compromise patient safety or interfere with evaluation of the study drug (including but not limited to human immunodeficiency virus [HIV] and hepatitis C virus [HCV])
Known human immunodeficiency virus (HIV), hepatitis B Virus (HBV), or hepatitis C Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted)
Known to have acute or chronic active hepatitis B infection, hepatitis C infection, or known to have human immunodeficiency virus (HIV) infection
Patients with human immunodeficiency virus (HIV) or active hepatitis B or hepatitis C infection are ineligible
Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; NOTE: HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) testing is not required
Human immunodeficiency virus (HIV) seropositive, or active hepatitis A, B, or C infection
Patients with human immunodeficiency virus (HIV) or active hepatitis B or hepatitis C infection are ineligible
Uncontrolled bacterial or viral infections, or known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.
Active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Patients with a known history of human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or tuberculosis infection; patients with a history of cleared hepatitis C (undetectable viral loads) are allowed
Active uncontrolled infection at study enrollment including known diagnosis of human immunodeficiency virus or chronic active hepatitis B or C infection
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Negative human immunodeficiency virus (HIV), hepatitis B and C, and tuberculosis (TB) test
Human immunodeficiency virus (HIV), hepatitis B or C documented infections
Known human immunodeficiency virus (HIV) or active hepatitis A, B, or C
Known history of human immunodeficiency virus (HIV) infection, active infection with hepatitis B virus or hepatitis C virus, or any uncontrolled active systemic infection
Patients with known human immunodeficiency virus (HIV) infection or chronic or acute hepatitis B or C are not eligible; Note: Patients do not need to have HIV, hepatitis B, or hepatitis C testing at screening
History of any chronic Hepatitis, active Hepatitis B or C, human immunodeficiency virus (HIV), or acquired immune deficiency syndrome (AIDS)
Active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Active hepatitis B, active hepatitis C, or positive for human immunodeficiency virus (HIV)
Patients with known chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded
Infection with human immunodeficiency virus (HIV) and/or chronic/active infection with hepatitis B virus or hepatitis C virus
History of human immunodeficiency virus (HIV) infection or active hepatitis B or C
Known active infection with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or HIV. Cleared HBV/HCV infection is not an exclusion, nor is HIV infection with cluster of differentiations 4 (CD4) counts >500 and an undetectable viral load.
DONOR: Positivity for HIV, hepatitis B (hepatitis B virus [HBV]), hepatitis C (hepatitis C virus [HCV]), human T-cell lymphotropic virus (HTLV-I/II)
Active systemic illness (infection including viral illnesses such as hepatitis and human immunodeficiency virus [HIV])
Any history of human immunodeficiency virus (HIV) or hepatitis B infection
Has evidence of active hepatitis B virus or hepatitis C virus
Patient has a known history of human immunodeficiency virus (HIV) infection or chronic, active hepatitis B (testing not mandatory)
As judged by the investigator, has any evidence of severe or uncontrolled systemic diseases such as active bleeding diatheses, is positive for human immunodeficiency virus (HIV), or has active hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
Known human immunodeficiency virus (HIV), active hepatitis A, or hepatitis B or C infection
Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); subjects who are seropositive because of hepatitis B virus vaccine are eligible
Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus.
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Known history of human immunodeficiency virus infection or an active hepatitis B or C virus infection (exception: this criteria does not apply to patients with cervical/anal tumours enrolling in Cohort 6)
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Known prior or current history of human immunodeficiency virus (HIV) and/or hepatitis B/C
Known active infection with human immunodeficiency virus (HIV), hepatitis B or C viruses (screening not required)
No human immunodeficiency virus (HIV) infection or active hepatitis B or C
Evidence of uncontrolled viral infection including Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), Human Herpes Virus-6 (HHV-6), Hepatitis Virus (HBV), or Hepatitis C Virus (HCV) based on assessment by the treating physician.
Known history of a positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
Serious infections including a history of active hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
Known seropositivity for, or active viral infection with, human immunodeficiency virus (HIV), hepatitis B virus (HBV) (unless due to vaccination), or hepatitis C virus (HCV); HIV-positive patients on combination antiretroviral therapy are ineligible
Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), or hepatitis C virus (HCV)
DONOR: Chronic viral infection including active hepatitis B, hepatitis C, HIV, or human T-lymphotropic virus (HTLV)-1/2
Subjects who active hepatitis B or C, or human immunodeficiency virus (HIV)
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
Active hepatitis B (hepatitis B virus [HBV]) or C (hepatitis C virus [HCV]) infection (negative serology required excluding those with are seropositive due to prior vaccination) and/or known history of human immunodeficiency virus (HIV)
Active hepatitis, known human immunodeficiency virus (HIV), or other condition that requires immunosuppressive therapy, including current use of high dose systemic corticosteroids
No known clinical finding or suspicion of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)
Current or chronic hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
Patients with known human immunodeficiency virus (HIV) infection or hepatitis
Known history of active tuberculosis (TB), human immunodeficiency virus (HIV) 1/2, hepatitis B or hepatitis C
True positive test results for human immunodeficiency virus (HIV) or hepatitis B or C
Human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection due to risk of progression while receiving immunosuppressive chemotherapy
Human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; HIV positive patients will be excluded
Have a serious concomitant systemic disorder including human immunodeficiency virus (HIV), active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorder or disease requiring high dose of steroids.
Uncontrolled bacterial or viral infections, or known human immunodeficiency virus (HIV), hepatitis B or C infection
Any positive history for human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), human T-cell lymphotropic virus (HTLV), hepatitis B or hepatitis C virus indicating acute or chronic infection
Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)
Known positive test for human immunodeficiency virus infection (HIV), or active hepatitis B or hepatitis C infection.
Known seropositivity for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B vaccine are eligible
Known history of human immunodeficiency virus (HIV) or active hepatitis C
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
The subject has a history of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), chronic hepatitis B or hepatitis C or is otherwise reasonably suspected to meet criteria for the diagnosis of a known congenital or acquired disorder causing systemic immunosuppression
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Known active acute or chronic infection including urinary tract infection, human immunodeficiency virus (HIV) or viral hepatitis
Known active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
Has a known human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV) infection
Known human immunodeficiency virus (HIV)-positive and on highly active antiretroviral therapy (HAART), and/or hepatitis B or C on treatment
Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Known human immunodeficiency virus (HIV) infection or active hepatitis A, B or C
Known active hepatitis B virus (HBV), human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection, are eligible)
Known active infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C or cytomegalovirus (CMV)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), active hepatitis B or hepatitis C
Has a known history of human immunodeficiency virus (HIV) (HIV1/2 antibodies), hepatitis B, or hepatitis C infection
Patients with human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C positive; or with a history of chronic active hepatitis or cirrhosis
DONOR: Active human immunodeficiency virus (HIV) or hepatitis B or C infection
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection (note: if not suspected, testing is not required at baseline)
Active uncontrolled infection; presence of latent or medication-controlled human immunodeficiency virus (HIV) and/or viral hepatitis is allowed
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
Ongoing or active systemic infection, known active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Subjects must not have active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection; testing is not required as part of this study
Known hepatitis B virus, hepatitis C virus or HIV infection
Patients known to be positive for hepatitis B surface antigen expression or with active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months), or with known human immunodeficiency virus (HIV) infection
Known immunosuppressive disease, autoimmune disease or human immunodeficiency virus infection, hepatitis B or hepatitis C
Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
Be on immunosuppressive therapy or have human immunodeficiency virus (HIV) infection or active hepatitis B or C
Patients with known hepatitis B or C or human immunodeficiency virus (HIV) infection
Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.
Patients with a known active infection, e.g., hepatitis B virus or hepatitis C virus; human immunodeficiency virus (HIV)-positive patients who are otherwise well and who do not have evidence of significant immune compromise are eligible
Other clinically significant disorders such as:\r\n* Known active infection requiring systemic treatment, infection with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, chronic hepatitis B or known or suspected active hepatitis C infection\r\n* Serious non-healing wound or ulcer\r\n* Malabsorption syndrome\r\n* Symptomatic hypothyroidism\r\n* Moderate to severe hepatic impairment (Child-Pugh B or C)\r\n* Requirement for hemodialysis or peritoneal dialysis\r\n* History of solid organ transplantation
Has known active infection with hepatitis B virus or hepatitis C virus
Active viral hepatitis or active human immunodeficiency virus (HIV) infection. Asymptomatic positive serology is not exclusionary.
Active hepatitis A, B, or C virus infection, or known human immunodeficiency virus (HIV) positive
Any evidence of severe or uncontrolled systemic disease, including, but not limited to, ongoing or active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
No known history of human immunodeficiency virus (HIV) 1 and 2, human T-lymphotropic virus (HTLV)-1, or active hepatitis B or hepatitis C
Known active hepatitis B infection, known history of hepatitis C or human immunodeficiency virus (HIV) infection
Patients with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Human immunodeficiency virus (HIV), human T-cell lymphotropic virus type 1 (HTLV-1), hepatitis B virus (HBV), and hepatitis C virus (HCV) negative
Must not have evidence of previous or current infection with hepatitis B virus
Subject has a known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)
Have a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), hepatitis B, or hepatitis C infection
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C.
DONOR: Hepatitis A, B and C, HIV 1 and 2, human T-lymphotropic virus (HTLV), varicella zoster virus (VZV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), West Nile virus, Syphilis Treponema, T cruzi (Chagas), cytomegalovirus (CMV), and the MPX nucleic acid test (NAT) individual donor testing (IDT) (human immunodeficiency virus [HIV]/hepatitis C virus [HCV]/hepatitis B virus [HBV]) will be tested as per national standard of care guidelines for transplant donors; donors who are HIV positive will be excluded; donors who are positive by serology for Hepatitis B or C are eligible as long as polymerase chain reaction (PCR) for ribonucleic acid (RNA)/deoxyribonucleic acid (DNA) is negative
Current or chronic hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
Ongoing or active systemic infection, known active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Current or chronic hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
Known active hepatitis C virus, or known active hepatitis B virus
Active hepatitis B or hepatitis C or known human immunodeficiency virus (HIV) infection
Known positive for human immunodeficiency virus (HIV); active hepatitis B (HBV) or hepatitis C (HCV) infection
Known history of seropositive for human immunodeficiency virus (HIV) antibodies (HIV1 and HIV2), hepatitis C antibody (Hep C Ab) or a hepatitis B carrier (positive for hepatitis B surface antigen [HBsAg])
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positivity
Known ongoing or known active systemic infection, known active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligible
Active hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) or hepatitis C
Known sero-positive for active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are sero-positive because of hepatitis B virus vaccine are eligible
An existing diagnosis of human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or any current laboratory findings or clinical signs and symptoms that suggest these conditions
Human immunodeficiency virus (HIV) positive (recipients who are positive for hepatitis B [hepatitis B virus (HBV)], hepatitis C [hepatitis C virus (HCV)] or human T-cell lymphotropic virus [HTLV]-I/II are not excluded from participation)
Known active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C that has not been documented to be cured
Patients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), human T-lymphotropic virus 1 (HTLV1) and/or HTLV2
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Patient has known human immunodeficiency virus (HIV) or hepatitis C infection; baseline testing for HIV or hepatitis C is not required
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion
Patients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Research participants who have tested human immunodeficiency virus (HIV) positive, or have active hepatitis B or C infection based on testing performed within 4 weeks of enrollment
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Positive for human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C
Serious illnesses, such as: cardiovascular disease (uncontrolled congestive heart failure, hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmia), bleeding disorders, autoimmune diseases, severe obstructive or restrictive pulmonary diseases, active systemic infections, and inflammatory bowel disorders; this includes human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or active hepatitis B virus (HBV) and hepatitis C virus (HCV)
Known active human immunodeficiency virus (HIV), hepatitis B or C or infection; exception for patients with hepatitis B on antivirals and low viral load, to be determined at the discretion of the investigator
Active and uncontrolled infection including but not limited to known infection with human immunodeficiency virus (HIV), active hepatitis B, or hepatitis C
Seroreactivity for human immunodeficiency virus (HIV), human T-lymphotropic virus type I (HTLV I) or II, hepatitis B virus (HBV), hepatitis C virus (HCV)
Has a known human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV) infection
Uncontrolled infection, including human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV)-1, hepatitis B or hepatitis C viremia
Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Known hepatitis B virus, hepatitis C virus or HIV infection
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Patients with a known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Active infection requiring treatment, known immunosuppressive disease, active systemic autoimmune diseases such as lupus, receipt of systemic immunosuppressive therapy, human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C
History of human immunodeficiency virus (HIV), hepatitis B, hepatitis C and human t-lymphotropic virus (HTLV)
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Positivity for human immunodeficiency virus (HIV)-1/HIV-2, Hepatitis B virus, and Hepatitis C virus active infection
Human immunodeficiency virus (HIV), hepatitis B, hepatitis C
Patients known to be human immunodeficiency virus (HIV)-positive or have active hepatitis B or C
History of chronic or recurrent infection including but not limited to human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Known positive for human immunodeficiency virus (HIV) or with known active infectious hepatitis, type A, B or C
Uncontrolled infection, defined as an infection which has not resolved spontaneously or does not show evidence of significant resolution after initiating appropriate therapy, excluding chronic asymptomatic viral infections (e.g., human papillomavirus [HPV], BK virus, hepatitis C virus [HCV], etc.)
Known to be positive for human immunodeficiency virus (HIV) or infectious hepatitis (type B or C)
DONOR: Must be free from risk factors for, and no clinical evidence of, infection due to relevant communicable disease agents and diseases including: human immunodeficiency virus; hepatitis B virus; hepatitis C virus; human transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease; treponema pallidum and human T-cell lymphotropic virus (HTLV) 1 and 2
Known positive for human immunodeficiency virus-1 (HIV-1), or active infection with hepatitis-B or -C
Known human immunodeficiency virus (HIV) or hepatitis B positivity or prior progressive multifocal leukoencephalopathy (PML)
Known active infection with HIV, hepatitis B virus, or hepatitis C virus
Known infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV)-I, hepatitis B, or hepatitis C
Positivity for human immunodeficiency virus (HIV)-1/HIV-2, hepatitis B virus, and hepatitis C virus active infection
Patients with history of human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
In suspected patients no active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Active infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) (can be pending at this time)
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV), hepatitis B virus; patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence\r\nof cirrhosis AND the patient’s liver function tests fall within the parameters set
Patients must be human immunodeficiency virus (HIV) negative, and have negative serologies for hepatitis C
Known human immunodeficiency virus (HIV) infection or chronic or acute hepatitis B or C\r\n* Note: patients who have a history of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are eligible, however, they must receive prophylactic antiviral therapy for 1-2 weeks prior to receiving study drug
Known sero-positive for active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are sero-positive because of hepatitis B virus vaccine are eligible
Patients with active human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection
Active or symptomatic infection including human immunodeficiency virus (HIV), viral hepatitis or chronic liver disease
Known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals is allowed.
Known seropositive and requiring anti-viral therapy for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
Have an ongoing or active infection, including but not limited to, the requirement for intravenous (IV) antibiotics, or a known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Testing is not required in the absence of history.
Patients with known active human immunodeficiency virus (HIV), hepatitis A, hepatitis B, or hepatitis C infection
Active infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), human T-cell lymphotropic virus (HBV), hepatitis C virus (HCV) (can be pending at this time)
Human immunodeficiency virus (HIV) infection, active hepatitis B or C infection, or evidence of liver cirrhosis
Hepatitis C infection, chronic infection with hepatitis B, infection with human immunodeficiency virus (HIV), or evidence of hepatic insufficiency
A known history of human immunodeficiency virus (HIV) seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment
Known infection with human immunodeficiency virus (HIV), hepatitis B or C
Documented evidence of negative tests for the presence of hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV)1 and HIV2 antibodies within the three months preceding study entry; subjects who do not have such evidence must undergo appropriate testing prior to virus administration
Patients with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection are ineligible
Known infection with human immunodeficiency virus (HIV), hepatitis B or C
History of human immunodeficiency virus (HIV), or known active hepatitis B or C infection.
Active infection including human immunodeficiency virus (HIV) and untreated hepatitis B, and hepatitis C. Screening for chronic conditions is not required.
Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or any active systemic viral infection requiring therapy (e.g., hepatitis B or C)
Known hepatitis B virus, hepatitis C virus or HIV infection
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus positive.
Positive test for hepatitis B hepatitis C, and / or human immunodeficiency virus (HIV) during screening, or within 3 months prior to first dose of study treatment
Any evidence of active infection including active Hepatitis B, Hepatitis C or human immunodeficiency virus
Subjects who have an active hepatitis B virus or hepatitis C virus infection requiring treatment as defined in the protocol
Known positive virology/serology for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B (surface antigen), or hepatitis C.
Patients with known human immunodeficiency virus, active hepatitis B or active hepatitis C
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), or hepatitis C virus (HCV)
Known history of Human Immunodeficiency Virus (HIV) or active infection with Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV) or any uncontrolled active systemic infection.
Subjects with known active hepatitis B or C infection, or hepatobiliary disease, or known history of immunodeficiency virus infection.
Known positive test result for human immunodeficiency virus or active hepatitis B or C virus infection
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Known infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
Has known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection based on positive tests during Screening
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Known active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, active or symptomatic viral hepatitis or chronic liver disease
Subject is positive for human immunodeficiency virus (HIV-1) chronic or active hepatitis B, or active hepatitis A or C
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.
Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)
Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.
Chronic hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive, that might affect host immunity
Ongoing, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
RENAL & BLADDER: Known evidence of an active infection requiring systemic therapy such as human immunodeficiency virus (HIV), active hepatitis, or fungal infection
Negative screening test results for hepatitis B, hepatitis C, and human immunodeficiency virus
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), hepatitis B (HepB), or hepatitis C (HepC) positive
Patients known positive for human immunodeficiency virus (HIV), or infectious hepatitis type B or C
Known history of human immunodeficiency virus or infection with hepatitis requiring antiviral therapy
Known history of human immunodeficiency virus (HIV) or hepatitis C (baseline testing is not required)
Subject is known to be seropositive for human immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C antibody (unless treated curatively)
No infection with human immunodeficiency virus (HIV) and no known history of hepatitis B or hepatitis C virus indicating acute or chronic infection or active tuberculosis (TB)
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection; subjects with laboratory evidence of cleared HBV and HCV infection will be permitted
Participants who have a known active infection requiring systemic therapy, including human immunodeficiency virus (HIV), hepatitis B, and hepatitis C
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)
Uncontrolled infection with human immunodeficiency virus (HIV) or chronic hepatitis B or C.
Positive human immunodeficiency virus (HIV) test, active tuberculosis, active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Participant has an active systemic fungal and/or known viral infection (for example, human immunodeficiency virus antibodies, hepatitis B surface antigen or hepatitis C antibodies)
Other viral infections:\r\n* Known to have acute or chronic active hepatitis B or hepatitis C infection\r\n* Known to have human immunodeficiency virus (HIV) infection\r\n* Prior therapy with viral-based tumor vaccine\r\n* Received live vaccine within 28 days prior to enrollment
Known active infection with human immunodeficiency virus, hepatitis B, or hepatitis C
Evidence of any of the following conditions per subject self-report or medical chart review\r\n* Any prior invasive malignancy within 5 years of enrollment that may affect outcome of study\r\n* Any non-invasive malignancy not treated with curative intent or with known active disease within 5 years before enrollment that may affect outcome of study\r\n* Major surgery or significant traumatic injury occurring within 4 weeks before enrollment\r\n* Active infection with hepatitis B virus or hepatitis C virus\r\n* Known infection with human immunodeficiency virus (HIV)\r\n* Active infection requiring IV anti-infective therapy
Active infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis) or other medical condition that would make prednisone/prednisolone corticosteroid) use contraindicated
Active Epstein-Barr virus (EBV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
Active hepatitis B virus (HBV) infection
The subject has a history of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), chronic hepatitis B or hepatitis C or is otherwise reasonably suspected to meet criteria for the diagnosis of a known congenital or acquired disorder causing systemic immunosuppression
Known history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Other viral infections\r\n* Known to have acute or chronic active hepatitis B or hepatitis C infection\r\n* Known to have human immunodeficiency virus (HIV) infection\r\n* Prior therapy with viral-based tumor vaccine\r\n* Received live vaccine within 28 days prior to enrollment
Patients with known active hepatitis B or C or human immunodeficiency virus (HIV) infection or with history of tuberculosis
Known chronic hepatitis B or C, or human immunodeficiency virus (HIV) infection
Known hepatitis B virus (HBV) or hepatitis C virus (HBV) infection
Patient is known to be human immunodeficiency virus (HIV) positive, or have chronic or active hepatitis B (core- or surface antigen-positive) or active hepatitis C infection
Known chronic infection with human immunodeficiency virus, hepatitis B, or hepatitis C.
Hepatitis B, hepatitis C, and human immunodeficiency virus (HIV) serology-positive (or known history of HIV seropositive status) participants are ineligible; hepatitis B, hepatitis C, and HIV serology-positive individuals were excluded from the pivotal pembrolizumab clinical trial in melanoma, so safety of this drug in this setting is unknown
Patients with history of human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) due to potentially increased risk of mithramycin toxicity in this population
Patients with chronic viral illnesses such as human immunodeficiency virus (HIV)-positivity and active hepatitis B or C are ineligible
Patients with known active hepatitis B virus (HBV) and hepatitis C virus (HCV) infections
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C
Known active or chronic human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection, or positive hepatitis B (Hep B) surface antigen; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowed
Patients with human immunodeficiency virus (HIV) or hepatitis, or known active cytomegalovirus (CMV), Epstein–Barr virus (EBV) or any other viral illness requiring treatment are ineligible
Known active human immunodeficiency virus (HIV) or hepatitis A, B, or C virus infection
Known chronic infections with human immunodeficiency virus (HIV), hepatitis B or C
Human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) seropositivity
Human immunodeficiency virus (HIV) and hepatitis c negative (serology)
Patient has a current active infectious disease or known positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), or hepatitis A virus (HAV)
Subjects with known seropositivity to human immunodeficiency virus (HIV), positive\n             for Hepatitis B, positive for Hepatitis C (antigen positive), or known hepatic\n             cirrhosis
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; patients must have negative testing for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) within 4 weeks prior to randomization
Have known seropositivity for human immunodeficiency virus, hepatitis C virus, hepatitis B surface antigen, or syphilis; does not require serologic confirmation as a study procedure
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus; patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters set above
Current infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C. Patients will have serologic testing performed during screening for HIV and hepatitis B and C. Any serologic results suggestive of an ongoing viral infection will be further investigated as necessary to clarify the patient’s status
Subjects who have a history of human immunodeficiency virus (HIV) infection or subjects who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment due to a theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection; subjects with chronic HBV or HCV infection are eligible at the investigator’s discretion if the subject is considered non-infectious based on serological markers
Subjects with known history of cirrhosis, human immunodeficiency virus (HIV), hepatitis B or C
Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with known human immunodeficiency virus (HIV) infection are eligible if not on antiviral agents and cluster of differentiation (CD)4 counts are adequate (>= 500)
Has a known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
Known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C (no additional laboratory tests for HIV, hepatitis [Hep] B, or Hep C are required for screening)
Patients with a known history of human immunodeficiency virus (HIV) infection or active hepatitis B or hepatitis C
Active human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Ongoing or active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis
Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Known active hepatitis B infection, known active hepatitis C infection, or known human immunodeficiency virus (HIV) carrier
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed)
Known hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (unless cleared) will be excluded
With human immunodeficiency virus (HIV)-positivity or active infectious hepatitis
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) infection: \r\n* Seropositive for HIV antibody \r\n* Seropositive for hepatitis C or positive for hepatitis B surface antigen (HbsAG)
Known human immunodeficiency virus (HIV), hepatitis B or C-positive patients (active, previously treated or both)
A known diagnosis of human immunodeficiency virus (HIV) infection or acquired immune\n             deficiency syndrome (AIDS), acute or chronic hepatitis B or hepatitis C infection, as\n             determined by medical history.
Patient must not be known to be human immunodeficiency virus (HIV)-positive, hepatitis B-positive, or hepatitis C-positive (with the exception of chronic or cleared hepatitis B virus [HBV] or hepatitis C virus [HCV] infection, which will be allowed)
Patients with active severe infection; known infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, or severe concurrent illness will be excluded from the study; HIV-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV) infection or known history of active hepatitis B or C infection
Patients with active severe infection; known infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, or severe concurrent illness
Patients with human immunodeficiency virus (HIV) disease or active viral hepatitis
Patients who have human immunodeficiency virus (HIV) or hepatitis C; patients would not be excluded for hepatitis B surface antigen positivity if on lamivudine or entecavir
Patients who have human immunodeficiency virus (HIV) or hepatitis C; patients would not be excluded for hepatitis B surface antigen positivity if on lamivudine
Active infection with hepatitis A, B or C virus
Patients known to be seropositive for human immunodeficiency virus (HIV) and active hepatitis, even if liver function studies are in the eligible range
Patient must not be known to have human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C, life-threatening illness unrelated to cancer, or any serious medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with participation in this study; patients will be tested for hepatitis B or C or HIV infection during screening if they are considered by the investigator to be at higher risk for these infections and have not been previously tested
Human immunodeficiency virus (HIV) or hepatitis B or C
Known seropositive for, or history of, active Human Immunodeficiency Virus (HIV) Hepatitis B Virus (HBV), Hepatitis C Virus (HCV)
Known infection with human immunodeficiency virus, or active hepatitis B or C, or other active clinically relevant liver disease.
Positive test for hepatitis B, C or HIV (Human Immunodeficiency Virus) virus
Subjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.
Has a known Human Immunodeficiency Virus (HIV), or a known, active Hepatitis B (HBV), or a known, active Hepatitis C (HCV) infection.
Known human immunodeficiency virus (HIV), or Hepatitis B or C.
Active and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness.
Known active hepatitis C virus, or known active hepatitis B virus
Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infections or positive human immunodeficiency virus (HIV) antibody results. Patients with sustained virologic response to HCV treatment or immunity to HBV from prior infection without cirrhosis may be included.
Evidence of active hepatitis B (HepB), hepatitis C (HepC), or Human Immunodeficiency Virus (HIV) infection.
Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration
Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
Patients with known human immunodeficiency virus (HIV) or active infection with hepatitis C virus or hepatitis B virus (testing is not mandatory)
Is positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C
Known human immunodeficiency virus (HIV) or known active hepatitis B or hepatitis C infection for participants not receiving obinutuzumab pretreatment
Active or prior history of human immunodeficiency virus (HIV) infection, hepatitis B or C (screening for all three is mandatory prior to study)
Known history of human immunodeficiency virus (HIV) infection, or seropositive results consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.
Patients with active liver disease, for example, due to hepatitis B virus, hepatitis C virus, autoimmune hepatic disorder, or sclerosing cholangitis
The patient has known positive status for human immunodeficiency virus (HIV) active or chronic Hepatitis B or Hepatitis C.
Known history of human immunodeficiency virus (HIV) seropositivity, acute or chronic active hepatitis B or C infection, or other serious chronic infection requiring ongoing treatment
Ongoing or active infection, known human immunodeficiency virus (HIV) positive, active hepatitis B or C infection.
Significant life-threatening extra-hepatic disease, including patients who are on dialysis, have unresolved diarrhea, have serious unresolved infections including patients who are known to be human immunodeficiency virus (HIV) positive or have acute hepatitis B virus (HBV) or hepatitis C virus (HCV)
Known active infection with HIV or Hepatitis B or C virus
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Has evidence of interstitial lung disease, active non-infectious pneumonitis, a known additional malignancy that is progressing or requires active treatment, an active infection requiring intravenous systemic therapy, an active autoimmune disease that has required systemic therapy, a known Human Immunodeficiency Virus (HIV), Hepatitis B (HBV), or Hepatitis C (HCV) infection
Evidence for infection including wound infections, Human Immunodeficiency Virus (HIV) or any type of Hepatitis
Patients must not have known human immunodeficiency virus (HIV), hepatitis B or C positivity
Subjects is positive for human immunodeficiency virus (HIV); chronic or active hepatitis B or active hepatitis A, or C
Have known active fungal, bacterial, and/or viral infection, including human immunodeficiency virus (HIV) or hepatitis virus (A,B, or C).
Subject known to have acute or chronic active hepatitis B, hepatitis C, or human immunodeficiency virus infection will also be excluded.
Known human immunodeficiency virus, viral hepatitis, or tuberculosis positivity
Known Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV) infection, or evidence of active Hepatitis B Virus (HBV) infection
Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, autoimmune hepatic disorders, sclerosis cholangitis or active infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus
Known Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV) infection, or evidence of active Hepatitis B Virus (HBV) infection.
Positive for human immunodeficiency virus (HIV), Hepatitis B or C
Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C
Is positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C
Known active or chronic hepatitis B or C or human immunodeficiency virus (HIV)
Active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease.
Patients with human immunodeficiency virus (HIV), chronic hepatitis B, or chronic hepatitis C (known from the existing medical record)
Seropositive for human immunodeficiency virus, hepatitis B, or hepatitis C
Have active or uncontrolled clinically serious hepatitis B virus or hepatitis C virus infection.
Known active hepatitis B or C, or human immunodeficiency virus (HIV) infection
History of human immunodeficiency virus (HIV) infection, active hepatitis B (chronic or acute), or hepatitis C infection
Known infection with HIV or chronic infection with hepatitis B virus or hepatitis C virus
Known seropositive for human immunodeficiency (HIV) virus, hepatitis B surface antigen (HbsAg), or antibody to hepatitis C virus (anti-HCV).
Known history of human immunodeficiency virus (HIV) infection or chronic or active hepatitis B or hepatitis C requiring treatment with antiviral therapy.
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
Seropositive for or active viral infection with hepatitis B virus (HBV):
Known seropositive for or active infection with hepatitis C virus (HCV)
Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with human immunodeficiency virus (HIV), hepatitis B or C virus
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection;
EXCLUSION FOR COLLECTION OF T CELLS/PBMCS: Patients with active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B
Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B vaccine are eligible
Human immunodeficiency virus (HIV) positive patients or hepatitis B or C positive patients
Human papilloma virus-associated cancers\r\n* Histologically proven squamous carcinoma of the anal canal, penile, vaginal, vulva, or refractory cervical cancer with progression or intolerance to at least one treatment regimen including cisplatin or carboplatin will be enrolled; human papilloma virus (HPV) confirmation is not required\r\n* Patients must have metastatic disease not amenable to surgical resection\r\n* If human immunodeficiency virus (HIV)+ positive, all patients infected with human immunodeficiency virus (HIV) and CD4+ T cell count > 400 cells/mm^3 may be eligible for study\r\n* Patients co-infected with hepatitis B virus and/or hepatitis C virus may be included in this study provided that their liver function tests remain within the limits listed above; patients must be followed by a hepatologist during the course of this study
Active uncontrolled infection. Active hepatitis B or C virus (HBV or HCV), or human immunodeficiency virus (HIV)infection.
Patients with known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection
Known history of human immunodeficiency virus (HIV), active hepatitis C virus, active hepatitis B\r\nvirus infection, or any uncontrolled active systemic infection \r\n* Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated
Known acute or chronic-active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Positive human immunodeficiency virus (HIV) or hepatitis B or C
Subject who has known seropositivity for or active infection for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).
Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Human immunodeficiency virus (HIV), active hepatitis B or C, or tuberculosis
Known history of human immunodeficiency virus or active infection with hepatitis virus or any uncontrolled active systemic infection.
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C
Seropositive for human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) per patient history
Active viral hepatitis or active human immunodeficiency virus infection
Subjects with positive human immunodeficiency virus (HIV) or hepatitis C at baseline by self-report
Subject has a known history of infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion; for guidance in defining active infection for hepatitis B, please refer to the World Health Organization (WHO) guidelines
Patient has a known history of human immunodeficiency virus (HIV) (testing not mandatory), active hepatitis B or C infection
Known active hepatitis C virus, or known active hepatitis B virus
Uncontrolled infectious diseases - requires negative tests for clinically suspected human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV).
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis (B or C)
Active human immunodeficiency virus (HIV), Hepatitis B Virus (HBV) or hepatitis C virus (HCV) infections at the time of screening. Subjects with laboratory evidence of HCV clearance may be enrolled.
Human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) or human T-lymphotropic virus (HTLV) I/II infections
Active infection with hepatitis B or C or human immunodeficiency virus (HIV)
Have active bacterial, fungal, and/or known viral infection (for example, human immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen [HBSAg], or hepatitis C antibodies). Screening is not required for enrollment.
Known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Subjects with positive human immunodeficiency virus (HIV) or hepatitis C at baseline by self report
Known severe and/or uncontrolled medical disorder that would impair ability to receive study treatment (i.e., uncontrolled diabetes, chronic renal disease, chronic pulmonary disease, human immunodeficiency virus [HIV], hepatitis B virus [HBV], hepatitis C virus [HCV], or active infection)
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known to be HIV positive, active hepatitis C virus, or active hepatitis B virus
Known human immunodeficiency virus (HIV), active hepatitis A, or hepatitis B or C infection
Known HIV infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia or at risk for HBV reactivation
Known seropositive for or active viral infection with hepatitis B virus (HBV) or/and human immunodeficiency virus (HIV).
Known history or active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis
History of hepatitis B or C, human immunodeficiency virus (HIV), tuberculosis or a chronic infection of any type
Patients with fever or any active systemic infections, including known human immunodeficiency virus (HIV), hepatitis B or C
Human immunodeficiency virus (HIV) positive or active infection requiring treatment (except for hepatitis virus)
Known human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection.
Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus
Subject has a known active hepatitis B or C infection, Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)
Active infection with human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) (can be pending at this time)
Negative screen for human immunodeficiency virus (HIV), hepatitis B virus (HBV) antigen, and hepatitis C virus (HCV); if testing was done within the past three months, there is no need to repeat testing, as long as documentation of results is provided to the study site; subjects must receive counseling and sign a separate informed consent for HIV testing
Known immunodeficiency or human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection; antibody to hepatitis B or C without evidence of active infection may be allowed
Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment or have an active infection that is clinically serious in the investigator's opinion.
Known positive for human immunodeficiency virus (HIV) or hepatitis B or C per institutional standard of care
Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C
Known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Known positive status for human immunodeficiency virus or active or chronic Hepatitis B or Hepatitis C.
Known human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C, or life-threatening illnesses unrelated to cancer.
Human Immunodeficiency Virus (HIV), or active Hepatitis C (HCV) virus. Escalation: active Hepatitis B (HBV); Expansion: Patients with Chronic HBV currently on medication will not be excluded.
Known active human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection on antiviral treatment
Hepatitis B or C or human immunodeficiency virus (HIV)
Active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or known active or chronic infection with human immunodeficiency virus; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection (including undetectable viral loads while on antiviral therapy) and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowed
Positive screening tests for human immunodeficiency virus (HIV), hepatitis B virus (Hep B), and hepatitis C virus (Hep C). If positive results are not indicative of true active or chronic infection, the patient can be treated.
Seropositive or active viral infection with hepatitis B virus, human immunodeficiency virus or hepatitis C virus.
Known seropositivity for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligible
Active infection with hepatitis B or C or human immunodeficiency virus (HIV)
Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligible
Active infection including tuberculosis, hepatitis B or C, or human immunodeficiency virus.
Known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)
Active infection with human immunodeficiency virus (HIV), hepatitis B Virus (HBV), or hepatitis C Virus (HCV)
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Patients with known active hepatitis B virus or hepatitis C virus acute or chronic infection
Known history of human immunodeficiency virus (HIV) and/or active Hepatitis B or C infections
Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis
Known infection with human immunodeficiency virus (HIV), hepatitis B or C
Subjects who have a history of human immunodeficiency virus (HIV) infection or subjects who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment.
Immunocompromised patients (other than that related to the use of corticosteroids) including patients confirmed to be human immunodeficiency virus (HIV) positive or have active viral hepatitis
Known positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
Known positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or C
Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive ( i.e. hepatitis B core antibody positive; quantitative deoxyribonucleic acid [DNA] negative) are eligible with appropriate prophylaxis
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection, or any uncontrolled active systemic infection \r\n* Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated
Subjects with known active hepatitis B virus (HBV) and hepatitis C virus (HCV) infection
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Current or chronic hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
The participant has active infection requiring systemic therapy, including active tuberculosis or known history of infection with the human immunodeficiency virus (HIV 1/2 antibodies), or hepatitis B (e.g., HBsAg reactive) and/or C virus (e.g., HCV RNA [qualitative] is detected).
Known seropositive for or active human immunodeficiency virus (HIV) infection or hepatitis B or C viral infection; patients who are seropositive because of hepatitis B virus vaccine are eligible
Known diagnosis of human immunodeficiency virus (HIV) or hepatitis C (testing is not mandatory)
Human immunodeficiency virus (HIV)-positive patients or with history of hepatitis or with current chronic or active hepatitis; a past history of hepatitis A is allowed
Known hepatitis B or C virus, or human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV), active hepatitis B virus (HBV), or active hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBC and HCV infection, which will be allowed)
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Known to be human immunodeficiency virus (HIV) positive or has untreated, active hepatitis B.
Has a known history of Human Immunodeficiency Virus (HIV) or Hepatitis C (baseline testing is not required).
Active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or known active or chronic infection with human immunodeficiency virus.
History of human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection.
Known history of human immunodeficiency virus (HIV), active Hepatitis B or C
Known active human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV)
Clinically active infection as judged by the treating investigator (? Grade 2 by CTCAE v4) including known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known seropositive and requiring anti-viral therapy for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
Known history of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C
Subjects with a known history of hepatitis B or C or human immunodeficiency (HIV) infection.
Active infection including hepatitis B, hepatitis C or human immunodeficiency virus (HIV);
Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or hepatitis C or tuberculosis
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed)
Patients with clinically evident Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C virus (HCV), or Epstein-Barr virus (EBV) infection are excluded.
DONOR: No positive testing for viral infection (hepatitis B surface antigen [HbsAg], human immunodeficiency virus (HIV), hepatitis C virus [HCV])
Known sero-positive for active or past viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are sero-positive because of hepatitis B virus vaccine are eligible
True positive test results for human immunodeficiency virus (HIV) or hepatitis B or C
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion
Active infection including hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
Immunocompromised subjects or those with autoimmune conditions, active hepatitis or positive for human immunodeficiency virus (HIV)
Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV).
Participant is known to be seropositive for human immunodeficiency virus (HIV), known to have hepatitis B surface antigen positivity, or history of to have a history of hepatitis C
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive.
Patients with known positivity for human immunodeficiency virus (HIV) or active hepatitis B or C; baseline testing is not required
Known hepatitis B virus, hepatitis C virus or HIV infection
Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) or any uncontrolled active systemic infection.
Patients must be test negative for human immunodeficiency virus (HIV), hepatitis B and C
Subject is human immunodeficiency virus (HIV) positive or has chronic hepatitis B or hepatitis C virus requiring treatment
Participants with known infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
Known diagnosis of human immunodeficiency virus, hepatitis B, or hepatitis C.
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or intercurrent illness, unrelated to the tumor, requiring active therapy
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or hepatitis C or tuberculosis
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Patients with known positivity for human immunodeficiency virus (HIV), or hepatitis C; baseline testing for HIV and hepatitis C is not required
Subjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.
Known seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Is known to have human immunodeficiency virus (HIV) or has active hepatitis C virus (HCV), or active hepatitis B virus (HBV)
Patients with known human immunodeficiency virus (HIV), hepatitis B or hepatitis C (active or carriers)
Known human immunodeficiency virus (HIV), hepatitis B and hepatitis C infection
Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) or any uncontrolled active systemic infection.
Positive screening tests for human immunodeficiency virus (HIV), hepatitis B (hep B), and hepatitis C (hep C) (referencing blood draw at leukapheresis screening); if positive results are not indicative of true active or chronic infection, the patient can be treated
COHORT A: No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C (negative screening tests required)
Known active uncontrolled human immunodeficiency virus (HIV) or hepatitis C infection
Subjects with known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV)
Positive human immunodeficiency virus (HIV), hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection
As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), hepatitis B (HepB), or hepatitis C (HepC) positive
Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
Subjects with known diagnosis of human immunodeficiency virus (HIV) or chronic active Hepatitis B or C; viral testing is not required; subjects with a history of Hepatitis B and/or C are allowed on trial if the virus is undetected at the time of enrollment
Comorbidities or prior conditions:\r\n* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\r\n* Prior organ transplantation including allogenic stem-cell transplantation\r\n* Known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy\r\n* Known history of active TB (Tuberculosis)\r\n* Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome\r\n* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening or positive serologies indicating prior infection\r\n* Active infection requiring systemic therapy\r\n* Has evidence of interstitial lung disease or active, non-infectious pneumonitis\r\n* Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection
Active human immunodeficiency virus (HIV) or hepatitis B or C with positive viral load, requiring anti-viral therapy
Known human immunodeficiency virus (HIV) or active hepatitis B or C viral infection
Subjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.
Known seropositivity for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligible; patients who are seropositive for HCV, but have a negative viral load are also eligible; documentation that the patients have completed a course of therapy for HCV is required and will be obtained
Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Patients must not have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Patients known to be human immunodeficiency virus (HIV) or hepatitis B and/or C positive are not eligible for participation; NOTE: HIV and hepatitis testing is not required for study participation
Subjects with known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV), because eltrombopag is hepatically cleared, and underlying hepatic impairment may lead to an increased risk of hepatotoxicity. Eltrombopag has not been evaluated with combination antiretroviral regimens.
DONOR: Donors who are HIV-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection
Known history of human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antibiotics
Patients with active liver disease, for example, due to hepatitis B virus, hepatitis C virus, autoimmune hepatic disorder, or sclerosing cholangitis
Active hepatitis B or C virus infection, or known human immunodeficiency virus(HIV) positive
Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or active hepatitis C.
A known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis
Seroreactivity for human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV) I or II, hepatitis B virus (HBV), hepatitis C virus (HCV)
Patients with human immunodeficiency virus (HIV), active hepatitis B or hepatitis C infection
Known infection with human immunodeficiency virus, Hepatitis B, or Hepatitis C
Active or chronic systemic infection, including viral hepatitis, human immunodeficiency virus (HIV), mycobacteria, tuberculosis (TB), or other opportunistic infections
Known human immunodeficiency virus (HIV) or active hepatitis B or C infection
Positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
Documentation of hepatitis B virus and hepatitis C virus serology is required
Clinical evidence of active infection of any type, including hepatitis B or C virus
Known hepatitis B virus, hepatitis C virus or HIV infection;
Known seropositive and requiring anti-viral therapy for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
Known prior positivity for active human immunodeficiency virus (HIV) or infectious hepatitis, type B or C
Known hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Patients with human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C positive; or with a history of chronic active hepatitis or cirrhosis
Known or tests positive for human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV-1), hepatitis B or hepatitis C.
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C
Patients with a known history of infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis
Active human immunodeficiency virus (HIV), hepatitis B and hepatitis C
Active human immunodeficiency virus (HIV), hepatitis A, B or C infection
Negative serology tests for human immunodeficiency virus (HIV) Ab/Ag Combo, and for active hepatitis B or hepatitis C, within 14 days of first peripheral blood collection for sipuleucel-T
Active human immunodeficiency virus 1 (HIV-1), hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection
Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Clinically relevant active infection including active hepatitis B or C or human immunodeficiency virus (HBV, HCV, or HIV) or any other concurrent disease
No additional screening intended for human immunodeficiency virus (HIV) or hepatitis infection
Known chronic infection with human immunodeficiency virus (HIV) or viral hepatitis
Known history of human immunodeficiency virus or hepatitis C, or active infection with hepatitis B or C
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known or suspected human immunodeficiency virus (HIV), hepatitis B surface antigen-positive status or known or suspected active hepatitis C infection.
Known history of human immunodeficiency virus (HIV), hepatitis B and hepatitis C (testing is not necessary if patient does not have history of these diseases, and no risk factors for acquisition of these viruses)
Known human immunodeficiency virus (HIV) infection, hepatitis B or Hepatitis C infection
Documented human immunodeficiency virus (HIV), active bacterial infections, active or chronic hepatitis B, or hepatitis C infection
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus positive.
Presence of active hepatitis C virus (HCV) or hepatitis B virus (HBV) infection, history of human immunodeficiency virus (HIV), or other uncontrolled systemic infection
Patients with a history of human immunodeficiency virus (HIV) infection; active viral infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B or C
Known active infection, or on antiretroviral therapy for human immunodeficiency virus (HIV) disease or positive test for chronic hepatitis B or C infection
Known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters set in inclusion criteria number 8c, “hepatic function”
Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection
Comorbid conditions: Addison’s disease, autoimmune hepatitis, hepatitis B, hepatitis C, acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV), lupus erythematosus, mixed connective tissue disease, rheumatoid arthritis
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; patients should be assessed for high risk behaviors that may result in these infections, such as intravenous drug use or multiple sexual partners; the assessment should be noted
Known infection with human immunodeficiency virus (HIV), human T-lymphotropic virus 1 (HTLV-I), hepatitis B, or hepatitis C
Known seropositive for or active viral infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV)
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion
Positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) or other viral hepatitis or cirrhosis from any cause
Active hepatitis C or positive tests for human immunodeficiency virus (HIV)
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Active hepatitis or human immunodeficiency virus (HIV) infection
Patients with human immunodeficiency virus (HIV) and active hepatitis B or hepatitis C infection are ineligible
Have active bacterial, fungal, and/or known viral infection (for example, human immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen [HBSAg], or hepatitis C antibodies) Screening is not required for enrollment
Known seropositive for an active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
Known Human Immunodeficiency Virus (HIV) infection, chronic hepatitis B or C (unless associated with hepatocellular cancer)
Patients who are known to be human immunodeficiency virus (HIV), hepatitis B, or hepatitis C positive
Seropositive for human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) per patient history
MATCHED RELATED DONOR: Donors must be human immunodeficiency virus (HIV) negative, human T-cell lymphotropic virus (HTLV) negative, hepatitis B virus surface antigen (HBsAg) negative
Positive test results for human immunodeficiency virus (HIV), human T-lymphotropic virus 1 (HTLV1), hepatitis C or chronic hepatitis B
Seronegativity for human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV1), hepatitis
Patients known to be seropositive for human immunodeficiency virus (HIV) and/or active hepatitis, even if liver function studies are in the eligible range
Known positivity for human immunodeficiency virus (HIV) or hepatitis C with uncontrolled disease; baseline testing for HIV and hepatitis C is not required
Known Human immunodeficiency virus (HIV) infection or active hepatitis A, B, or C
Human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C infection
Patient is known to be positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B, or C
Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis b virus vaccine are eligible
History of human immunodeficiency virus (HIV) or an active and uncontrolled infection with hepatitis C virus (HCV) or hepatitis B virus (HBV)
Known active hepatitis B (HBV), hepatitis C (HCV) or human immunodeficiency virus (HIV) infections; Note: pretesting is not required
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Negative virology/serology for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B (surface antigen), and hepatitis C
Patients with known active viral hepatitis or known human immunodeficiency virus (HIV) infection
Patients with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B (HBV) or C (HCV) or active hepatitis
Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and/or Hepatitis C Virus (HCV) infection.
Known Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV), and/or active Hepatitis C Virus (HCV) infection.
No known human immunodeficiency virus (HIV) infection or chronic hepatitis B or hepatitis C infection
Known history of Human Immunodeficiency Virus (HIV) infection or chronic hepatitis B or C
Evidence of infection with human immunodeficiency virus (HIV) or viral hepatitis
DONOR: Virology testing including cytomegalovirus (CMV), human immunodeficiency virus (HIV), Epstein–Barr virus (EBV), human T-lymphotropic virus (HTLV), rapid plasma reagin (RPR), hepatitis A, B and C will be performed within 30 days of donation
Active and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.
Known active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection, are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Positive for HIV (Human Immunodeficiency Virus) or with active hepatitis B and/or C
Subjects known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection
Is positive for Human Immunodeficiency Virus (HIV) and/or Hepatitis B or C
Known history of human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antibiotics
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.
Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection at the time of screening
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis B/C
HIV or human T-lymphotropic virus (HTLV) I/II positive, hepatitis C or chronic active hepatitis B
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV), hepatitis B virus\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters set
Active, uncontrolled bacterial, fungal or viral infection, including hepatitis B, hepatitis C, known human immunodeficiency virus or acquired immunodeficiency syndrome related illness.
Known active Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infections. Subjects with laboratory evidence of HBV clearance may be enrolled
Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligible
Known active infection with human immunodeficiency virus (HIV), hepatitis B or C
Active infection with Hepatitis B virus or Hepatitis C virus
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Have a serious concomitant systemic disorder including human immunodeficiency virus (HIV), active hepatitis B virus (HBV), active HCV, active autoimmune disorder or disease requiring high dose of steroids
Documented negative serologic testing for human immunodeficiency virus (HIV), hepatitis B (unless serologically positive due to prior vaccination), and hepatitis C within the year prior to enrollment (note: for guidance in defining active infection for hepatitis B, please refer to the WHO guidelines)
Known human immunodeficiency virus (HIV) and/or active Hepatitis B or C infections
Uncontrolled human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).
Known history of, or active hepatitis B virus (HBV), hepatitis C virus (HCV) or active tuberculosis
Known ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Also, known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Has known, previously diagnosed human immunodeficiency virus infection or active chronic hepatitis B or C.
Known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C
Ongoing or active systemic infection, history of hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Active hepatitis B infection, active hepatitis C infection or known human immunodeficiency virus (HIV) carrier
Known history of human immunodeficiency virus or active infection with hepatitis C virus or hepatitis B virus or any uncontrolled active systemic infection
Subject has known historical or active infection with HIV (human immunodeficiency virus), hepatitis B, or hepatitis C or subject receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the Investigator, increase the risk of serious neutropenic complications.
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed); HIV-positive patients on combination antiretroviral therapy are ineligible
Active infection requiring systemic therapy, including known human immunodeficiency virus (HIV), acquired immunodeficiency syndrome-related illness, or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
Any known positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy; baseline testing is not required
Known clinically significant infections, including human immunodeficiency virus (HIV) and active hepatitis B or C
Patients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Pts with known human immunodeficiency virus (HIV) or hepatitis C virus (HCV) disease (routine testing is not needed if not clinical indicated)
DONOR: not human immunodeficiency virus (HIV)-1, HIV-2, hepatitis C virus (HCV), hepatitis B core or human T-lymphotropic virus (HTLV)-I/II seropositive; hepatitis B surface antigen (HB S ag) (-); meet other infectious disease screening criteria utilized by NBAH Blood Center
Patients with known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both)
Active, life threatening or clinically significant uncontrolled systemic infection, known human immunodeficiency virus (HIV)-related illness, hepatitis B (Hep B) or hepatitis C (Hep C) infection
Known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis (hepatitis B or hepatitis C)
positive serology for human immunodeficiency virus (HIV), hepatitis B or hepatitis C or have HIV-AIDS, or active hepatitis B or C.
Known ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Patients with known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) or other infectious hepatitis
Patients with previously known infection with human immunodeficiency virus (HIV) or active viral hepatitis are ineligible; (diagnostic testing for these infections will be done only if clinically indicated)
Ongoing or active infection including known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C (HCV); testing for these viruses is not required in the absence of a history of infection
Patients with known human immunodeficiency virus (HIV), or known active hepatitis B or C infections
Known human immunodeficiency virus (HIV) positivity or acquired immune deficiency syndrome (AIDS)-related illness, active hepatitis B virus, or active hepatitis C virus
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, or HIV-seropositive
Positive serology for Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV); presence in the serum of the antigens HBs
Patients with known human immunodeficiency virus (HIV) or hepatitis B or C
Has known human immunodeficiency virus or acquired immune deficiency syndrome, hepatitis B, hepatitis C, connective tissue disease, or other clinical diagnosis, ongoing or intercurrent illness that in the Investigators opinion should preclude the subject from participation;
Known human immunodeficiency virus (HIV) or hepatitis B or C infection
Negative screen for human immunodeficiency virus (HIV), hepatitis B virus (HBV) antigen, and hepatitis C virus (HCV); if testing was performed during the previous 3 months, there is no need to repeat testing, as long as documentation of results is provided to the study site; subjects must receive counseling and sign a separate informed consent form for HIV testing
Patients with active hepatitis B or C infections or a history of human immunodeficiency virus (HIV) infection
Positive for human immunodeficiency virus (HIV) or hepatitis B or C
Known positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C
Negative screen for human immunodeficiency virus (HIV), hepatitis B virus (HBV) antigen, and hepatitis C virus (HCV); if testing was performed during the previous 3 months, there is no need to repeat testing, as long as documentation of results is provided to the study site; subjects must receive counseling and sign a separate informed consent form for HIV testing
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Active symptomatic fungal, bacterial and/or viral infection including positive serologies for human immunodeficiency virus (HIV), H\\human T-lymphotropic virus 1 (HTLV-1), 2, hepatitis C virus (HCV) or hepatitis B virus (HBV) (acute or chronic infection based on Center for Disease Control and Prevention [CDC] guidelines) within 30 days of registration; (antibody, antigen and nucleic acid tests acceptable, depending on institutional standards)
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; must test during screening if history is not known
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known human immunodeficiency virus (HIV) infection or active hepatitis B virus or hepatitis C virus infection.
Serious concurrent illness or clinically-relevant active infection, including, but not limited to the following:\r\n* Known active hepatitis B or C (NOTE: testing is not required)\r\n* Known human immunodeficiency virus (HIV) infection (NOTE: testing is not required)\r\n* Varicella-zoster virus (shingles)\r\n* Cytomegalovirus infection\r\n* Any other known concurrent infectious disease, requiring IV antibiotics within 2 weeks of first dose of mirvetuximab soravtansine
Clinically significant infections including human immunodeficiency virus (HIV), syphilis, and active hepatitis B or C
Have known fungal, bacterial, and/or viral infection, including human immunodeficiency virus (HIV) or hepatitis virus (B or C);
Known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C viruses
Clinically significant history of liver disease, current alcohol abuse, or current known active infection with HIV, hepatitis B virus, or hepatitis C virus
Previously known infection with human immunodeficiency virus (HIV); or, hepatitis B or C requiring treatment;
Known and actively treated infection with human immunodeficiency virus (HIV), hepatitis B or C
Known human immunodeficiency virus (HIV) or active hepatitis B or C infection
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus
Infection with Human immunodeficiency virus (HIV) or hepatitis B virus, hepatitis C\n             virus
Known sero-positive for active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are sero-positive because of hepatitis B virus vaccine are eligible
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required.
Active hepatitis B and C virus infection
Hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)-positive participants with active infection
Patients with known active hepatitis B, C or human immunodeficiency virus (HIV) infections on initial assessment
Known active human immunodeficiency virus (HIV) infection, hepatitis B or C
Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients with prior exposure to hepatitis, but no evidence of active or chronic infection, may be eligible
Known active infection with hepatitis A, B or C virus
Subject with known hepatitis B surface antigen (HBsAg) positive status; or known or suspected active hepatitis C infection; or known human immunodeficiency virus (HIV) positive.
Known or tests positive for human immunodeficiency virus, hepatitis B, or hepatitis C
Known infection with hepatitis B virus (HBV) and hepatitis C virus (HCV); testing may have been done up to 3 months prior to treatment
Infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or receiving immunosuppressive or myelosuppressive
Subject has a known infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or subject receiving immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications.
Known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
Active hepatitis B infection, active hepatitis C infection or known human immunodeficiency virus (HIV) carrier
Known human immunodeficiency virus (HIV) infection or active hepatitis B (defined as hepatitis B surface antigen–positive) or C (defined as hepatitis C antibody–positive)
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C
Patient with known historical or active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Known human immunodeficiency virus infection, or hepatitis B virus (HBV) viremia or hepatitis C virus (HCV) viremia; screening for the study does not require assessment for these infections if not already known; any other condition that, in the opinion of the investigator, may compromise the safety, compliance of the patient, or would preclude the patient from successful completion of the study
Known history of infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive)
Acute hepatitis, known human immunodeficiency virus (HIV), or active uncontrolled infection
Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C.
A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus, or Hepatitis C Virus infection.
Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligible
Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted).
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Subjects who are known to have a history of or active human immunodeficiency virus (HIV) or active hepatitis B and/or C
Have known hepatitis B or C, or human immunodeficiency virus infection
Human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; negative screening tests for HIV, hepatitis B, and hepatitis C are required
Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C.
No infection with human immunodeficiency virus (HIV) and no active infection with hepatitis B and no active or chronic infection with hepatitis C
Known hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Known to be positive for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection
Concomitant diseases/conditions as unstable angina, myocardial infarction, symptomatic congestive heart failure or asymptomatic with left ventricular ejection fraction (LVEF) ? 50%, dyspnea, infection by human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, active uncontrolled infection, pleural or pericardial effusions, myopathy, limitation of the patient's ability to comply with the treatment or to follow-up the protocol, any other major illness
Patients with known human immunodeficiency virus (HIV), hepatitis B or C (however, if patients have previously been treated for hepatitis B or C and have undetectable viral loads, they can be considered eligible for trial)
History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Patients with a known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
No human immunodeficiency virus (HIV) infection, active hepatitis B infection, or active hepatitis C infection
Known seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).
Known active hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection.
Known intercurrent infections (including hepatitis C virus and human immunodeficiency virus or other conditions), or clinical evidence of these conditions
Known human immunodeficiency virus (HIV) positive or hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
Patients with known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.
Current known active infection with human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C virus; for patients who are known carriers of hepatitis B virus (HBV), active hepatitis B infection must be ruled out based on negative serologic testing and/or determination of HBV deoxyribonucleic acid (DNA) viral load per local guidelines
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C. Testing is not required in the absence of clinical findings or suspicion.
Active Human Immunodeficiency Virus (HIV) or hepatitis B or C infection
Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B or C (testing is not mandatory for study entry)
Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection)
Known history of hepatitis B virus (HBV), hepatitis C virus (HCV), or active tuberculosis. Known history of human immunodeficiency virus (HIV) type 1/2 or other immunodeficiency disease.
Patients with a history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded because of potential effects on immune function and/ or possible drug interactions
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections are excluded
Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis C virus or hepatitis B virus
Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B surface antigen.
Infection with human immunodeficiency virus, hepatitis B, or hepatitis C
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Known positive serology for the human immunodeficiency virus (HIV), active hepatitis C, and/or active hepatitis B.
Subjects may not have known human immunodeficiency virus (HIV), active hepatitis A, or hepatitis B or C infection
Seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).
The patient has known positive status for human immunodeficiency virus (HIV), active or chronic Hepatitis B or Hepatitis C.
Current evidence or previous medical history of (ie, any absolute risk of latent infection) hepatitis B or C, any active hepatitis, or human immunodeficiency virus (HIV) infection. Active clinically serious infections > CTCAE Grade 2.
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Hepatitis B Virus, or Hepatitis C Virus infection (subjects with laboratory evidence of Hepatitis B Virus clearance may be enrolled).
Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV) will be excluded; patients with HIV who have adequate cluster of differentiation (CD)4 count, not requiring antiretroviral medication will not be excluded
Known active infection with HIV, Hepatitis B or C virus
Known active hepatitis B virus infection
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Known or suspected human immunodeficiency virus (HIV) or hepatitis A(acute), B or C infection
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis B or C; baseline testing for HIV and hepatitis C is not required
Known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C
Known human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
Has Known human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known Human Immunodeficiency Virus (HIV) positivity or active infectious hepatitis A, B or C
Known human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus positive status
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required; this is due to the unknown effects of AMG102
Patients known to be positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B or C requiring active therapy (hepatitis B seropositivity due to hepatitis [Hep] B virus vaccine is not an exclusion); patients on combination antiviral therapy are ineligible; appropriate studies will be undertaken in this patient population
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.
Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; testing for these is not required at baseline
Known human immunodeficiency virus, Hepatitis B or Hepatitis C infection.
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Uncontrolled infection, including human immunodeficiency virus (HIV), human T-cell lymphotropic virus type 1 (HTLV-1), hepatitis B or hepatitis C viremia
Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
Patients with human immunodeficiency virus infection, hepatitis B, or hepatitis C due to confounding effects on immune system
Patients with human immunodeficiency virus infection, hepatitis B, or hepatitis C infection due to confounding effects on immune function
Patients with human immunodeficiency virus infection, hepatitis B, or hepatitis C infection
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known positive test for human immunodeficiency virus infection, hepatitis C virus, acute or chronic hepatitis B infection, or any co-morbid disease that would increase risk of toxicity.
Currently known active infection with HIV, hepatitis B or C virus
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Known evidence of an active infection requiring systemic therapy such as human immunodeficiency virus (HIV), active hepatitis, or fungal infection
Active infection including tuberculosis (TB), hepatitis B, hepatitis C, or human immunodeficiency virus. Note: TB testing will be at the discretion of the treating physician and should be in line with local practice
Known history of human immunodeficiency virus (HIV) or active hepatitis C Virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Positive history of human immunodeficiency virus (HIV), active hepatitis B or active hepatitis C or severe/uncontrolled intercurrent illness or infection
Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following, are not eligible: \r\n* Ongoing or active infection requiring systemic treatment\r\n* Symptomatic congestive heart failure (>= class 3)\r\n* Unstable angina pectoris\r\n* Cardiac arrhythmia\r\n* Psychiatric illness/social situations that would, in the investigator’s opinion, limit compliance with study requirements\r\n* Known human immunodeficiency virus (HIV) infection\r\n* Known John Cunningham virus (JC) virus infection and/or progressive multifocal leukoencephalopathy (PML)\r\n* Known clinically active hepatitis A, B, or C infections\r\n** NOTE: Patients with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV) infection may enroll if other laboratory criteria are met; those with HBV surface antigen positivity may enroll only if maintained on appropriate suppressive antiviral therapy for the duration of enrollment in the trial\r\n* Second malignancy that requires active treatment\r\n* Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient’s safety or study endpoints
Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
Patients with clinically significant infection, including known human immunodeficiency virus (HIV), human herpesvirus-8 (HHV-8), hepatitis C infection, or known hepatitis B surface antigen positivity are not eligible
Known (historical) positive human immunodeficiency virus (HIV) serology, active hepatitis B, or active hepatitis C infection
Human immunodeficiency virus (HIV) infection; active hepatitis B infection; active hepatitis C infection
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Known positive serology for HIV (human immunodeficiency virus), active hepatitis B, and/or active hepatitis C infection
Known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
Active hepatitis C virus
Patients with active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Have an active systemic fungal and/or known viral infection (for example, human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C antibodies)
Has a known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
Active human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infections at the time of screening.
Patients must not have known history of hepatitis B, hepatitis C, human immunodeficiency virus (HIV); the use of physiologic doses of corticosteroids may be approved after consultation with the study chair
Patients with a known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C (testing not required as part of screening)
Active infection (such as human immunodeficiency virus [HIV] or viral hepatitis) or other medical condition that would make corticosteroid use contraindicated
Active hepatitis B or C virus
History of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C
Known chronic active hepatitis B or hepatitis C; human immunodeficiency virus (HIV)-positive patients receiving or are candidates for antiretroviral therapy are also excluded
Patients with known human immunodeficiency virus (HIV) infection or viral hepatitis
No known history of human immunodeficiency virus (HIV) or active hepatitis B or C
DONOR: Human T-cell lymphotropic virus (HTLV)/human immunodeficiency virus (HIV)(+) or hepatitis B or C antigen(+) donors
Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) within 2 months of registration and no history of disseminated cutaneous human papillomavirus (HPV) related disease
Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) within 2 months of registration
Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) within 2 months of registration
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Known seropositive, requiring anti-viral therapy, and with detectable viral load by polymerase chain reaction (PCR) for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
Human Immunodeficiency Virus, Hepatitis B Virus or Hepatitis C Virus infection.
Past history of tuberculosis (TB) or active infection with TB, human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
Have a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), hepatitis B, or hepatitis C infection
Any positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) indicating acute or chronic infection
Patient is known to have a history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests
Active infection with Hepatitis B virus or Hepatitis C virus
Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligible
Known positivity for human immunodeficiency virus (HIV) or active hepatitis B or C
Known seropositivity for human immunodeficiency virus (HIV) or diagnosis of acquired immunodeficiency syndrome (AIDS), positive for hepatitis B surface antigen, or seropositive for hepatitis C virus
Patients with a diagnosis of hepatitis or human immunodeficiency virus (HIV)
Patients with known active hepatitis B, hepatitis C, or seropositive human immunodeficiency virus (HIV); testing is not required in the absence of clinical suspicion
History of or current human immunodeficiency virus (HIV) or hepatitis C virus infection
History of known active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Active/chronic human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) infection
History of known active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Ongoing hepatitis B virus (HBV) infection
Known history of or known active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
DONOR: Positive for human immunodeficiency virus (HIV), active hepatitis B (hepatitis B virus [HBV]), hepatitis C (hepatitis C virus [HCV]) or human T?cell lymphotropic virus (HTLV?I/II)
Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV); this information will be obtained verbally from the patient
History of human immunodeficiency virus (HIV) or active hepatitis C
History of human immunodeficiency virus (HIV), hepatitis B, or active hepatitis C infection
History or serologic evidence of chronic viral infection (hepatitis B or C), human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
Evidence of any active uncontrolled infection (bacterial, viral or fungal) or evidence of natural exposure to hepatitis B, hepatitis C or human immunodeficiency virus (HIV) without demonstration of polymerase chain reaction (PCR) negativity for said virus; vaccination to hepatitis B is not an exclusion criterion
DONOR: All donors will be screened for the following:\r\n* Human immunodeficiency virus (HIV) I\r\n* HIV II\r\n* Hepatitis surface antigen (HbsAg)\r\n* Hepatitis B core antibody (HBc)\r\n* Hepatitis C virus (HCV)\r\n* Cytomegalovirus (CMV)\r\n* Syphilis\r\n* Human T-lymphotropic virus (HTLV I/II)\r\n* Epstein-Barr virus (EBV) and adenovirus immunoglobulin G (IgG) when feasible
Positive viral test of the donor for HIV-1, HIV-2, hepatitis B virus (HBV), hepatitis C virus (HCV), Treponema pallidum, human T-lymphotropic virus (HTLV) 1 (if tested), HTLV-2 (if tested), West Nile virus (WNV; if tested), or Zika virus (if tested)
Known serious infections, including a history of active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV); screening for these infections is not required for study enrollment
Positive for human immunodeficiency virus (HIV) or active infections for hepatitis B, and/or hepatitis C, based on medical history
Known active infection with human immunodeficiency virus (HIV), hepatitis A, B, or C
Subjects with positive human immunodeficiency virus (HIV) or hepatitis C at baseline
Known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C viruses
Known Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV) infection, or evidence of active Hepatitis B Virus (HBV) infection
Known human immuno virus infection.
Subjects with known HIV infection, chronic active hepatitis B or C virus (HBV/HCV) infection.
Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Known immunosuppressive disease, autoimmune condition, and/or chronic viral infection (eg, human immunodeficiency virus [HIV], hepatitis)
History of or active hepatitis B or hepatitis C or human immunodeficiency virus (HIV) infection
Known hepatitis A virus (HAV), hepatitis B virus (HBV) or hepatitis C virus (HCV) positivity with evidence of ongoing infection.
Subject is positive for human immunodeficiency virus (HIV-1), chronic or active hepatitis B, or active hepatitis A or C
Human immunodeficiency virus (HIV) positive or active hepatitis
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
Documented negative serologic testing for human immunodeficiency virus (HIV), hepatitis B (unless serologically positive due to prior vaccination), and hepatitis C =< 1 year prior to registration
Subjects must not have a history of human immunodeficiency virus, hepatitis B, or hepatitis C, except for the following:
Known positive status for human immunodeficiency virus (HIV) infection; known active hepatitis B or hepatitis C infection
Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).
Patients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are not eligible
Patient has a known history of human immunodeficiency virus (HIV) or active hepatitis B or active hepatitis C infection (testing not mandatory)
Patients who have a known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)
Known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)
Is known to be human immunodeficiency virus (HIV) positive and/or known to have active chronic or acute Hepatitis B or Hepatitis C
Active and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
Known active hepatitis B/C or HIV (human immunodeficiency virus) infection
Known history of human immunodeficiency virus (HIV), or active Hepatitis B or C.
Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Active systemic illness (infection including viral illnesses such as hepatitis and human immunodeficiency virus [HIV])
Active viral hepatitis or symptomatic human immunodeficiency virus (HIV) infection
Participants with known human immunodeficiency virus (HIV) infection, hepatitis B carrier state or with clinical evidence of hepatitis B
Known human immunodeficiency virus (HIV), active Hepatitis B (HBV) or Hepatitis C (HCV) infection
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted)
Have a serious concomitant systemic disorder (for example, active infection including human immunodeficiency virus [HIV], hepatitis C virus [HCV], hepatitis B virus [HBV] [ie, positive hepatitis B surface antigen [+HBsAg]]), or an autoimmune disease.
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
Active chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, active HIV, or cytomegalovirus (CMV) infection.
Known human immunodeficiency virus (HIV) seropositive or known hepatitis B or hepatitis C infection.
Has acute or chronic active hepatitis B virus or hepatitis C virus infection or received treatment with nucleotide analogs such as those used in the treatment of hepatitis B virus (eg, lamivudine, adefovir, tenofovir, telbivudine, entecavir), ribavirin, or interferon alpha within 12 weeks of initiation of study treatment.
Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).
Is previously diagnosed human immunodeficiency virus (HIV) infection or active hepatitis B or C.
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection (Exception: Subjects with chronic or cleared HBV and HCV infection and stable liver function tests [bilirubin, AST] will be allowed)
Known human immunodeficiency virus (HIV), recent hepatitis B virus (HBV), hepatitis C virus (HCV)
Clinically significant history of liver disease (including cirrhosis), current alcohol abuse, or current known active infection with HIV, hepatitis B virus, or hepatitis C virus
Human immunodeficiency virus (HIV), or active hepatitis B or C infection
History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)
Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Has acute or chronic active hepatitis B virus or hepatitis C virus infection or received treatment with nucleotide analogs such as those used in the treatment of hepatitis B virus (eg, lamivudine, adefovir, tenofovir, telbivudine, and entecavir), ribavirin, or interferon alpha within 12 weeks of initiation of study treatment.
Known seropositive for human immunodeficiency (HIV) virus, hepatitis B surface antigen (HbsAg), or antibody to hepatitis C virus (anti-HCV).
